The PTPRS antibody targets the protein tyrosine phosphatase receptor type S (PTPRS), a member of the receptor-type protein tyrosine phosphatase (RPTP) family. PTPRS plays critical roles in cellular signaling by regulating tyrosine phosphorylation, a key mechanism for controlling processes like cell adhesion, migration, and neuronal development. Structurally, PTPRS features an extracellular domain with fibronectin III repeats, a transmembrane region, and two intracellular phosphatase domains. Its extracellular interactions with ligands, such as heparan sulfate proteoglycans or cell adhesion molecules, modulate intracellular phosphatase activity, influencing pathways like Wnt/β-catenin and receptor tyrosine kinase signaling.
PTPRS is implicated in various physiological and pathological contexts. In the nervous system, it guides axon growth and synaptic plasticity. In cancer, PTPRS often acts as a tumor suppressor, with its downregulation linked to metastasis and poor prognosis. Dysregulation of PTPRS is also associated with autoimmune disorders and metabolic diseases.
Antibodies against PTPRS are essential tools for studying its expression, localization, and function. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry. Some antibodies target specific domains to explore ligand-binding or phosphatase activity. Validation of these antibodies includes testing in PTPRS-knockout models or siRNA-treated cells to ensure specificity. Commercial PTPRS antibodies are typically developed in rabbits or mice, with applications spanning basic research and clinical diagnostics, particularly in cancer and neurodegenerative disease studies.